Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Bladder Cancer

  Free Subscription


Articles published in Urol Int

Retrieve available abstracts of 83 articles:
HTML format



Single Articles


    August 2021
  1. STRUCK JP, Hennig MJP, Hupe MC, Moharam N, et al
    Discrepancy between German S3 Guideline Recommendations and Daily Urologic Practice in the Management of Nonmuscle Invasive Bladder Cancer: Results of a Binational Survey.
    Urol Int. 2021 Aug 31:1-11. doi: 10.1159/000518166.
    PubMed     Abstract available


  2. RUCKHER J, Lobitz J, Follmann M, Derenz S, et al
    Guideline-Based Quality Indicators for Kidney and Bladder Cancer in Germany: Development and Implementation.
    Urol Int. 2021 Aug 12:1-8. doi: 10.1159/000517893.
    PubMed     Abstract available


  3. TOHI Y, Miyauchi Y, Yamasaki M, Fujiwara K, et al
    Incidental Bladder Cancer Found on Cystoscopy during Prostate Biopsy: Prevalence, Pathological Findings, and Oncological Outcome.
    Urol Int. 2021 Aug 5:1-7. doi: 10.1159/000517895.
    PubMed     Abstract available


  4. RAVENTOS BUSQUETS CX, Semidey ME, Lozano Palacio F, Carrion Puig A, et al
    Is Tumor Budding a New Predictor for Early Cystectomy in pT1 High-Grade Bladder Cancer?
    Urol Int. 2021 Aug 5:1-9. doi: 10.1159/000517543.
    PubMed     Abstract available


    June 2021
  5. GAO T, Ji Y
    Long Noncoding RNA LINC00707 Accelerates Tumorigenesis and Progression of Bladder Cancer via Targeting miR-145/CDCA3 Regulatory Loop.
    Urol Int. 2021 Jun 30:1-15. doi: 10.1159/000514388.
    PubMed     Abstract available


    March 2021
  6. CHEN P, Chen J, He L, Du C, et al
    Identification of circRNA-miRNA-mRNA Regulatory Network in Bladder Cancer by Integrated Analysis.
    Urol Int. 2021 Mar 31:1-11. doi: 10.1159/000512066.
    PubMed     Abstract available


  7. LIU Y, Huang X, Guo L, Luo N, et al
    LINC00649 Facilitates the Cellular Process of Bladder Cancer Cells via Signaling Axis miR-16-5p/JARID2.
    Urol Int. 2021 Mar 31:1-9. doi: 10.1159/000506239.
    PubMed     Abstract available


  8. LIU Z, Zhang Y, Sun G, Ouyang W, et al
    Comparison of Thulium Laser Resection of Bladder Tumors and Conventional Transurethral Resection of Bladder Tumors for Non-Muscle-Invasive Bladder Cancer.
    Urol Int. 2021 Mar 30:1-6. doi: 10.1159/000514042.
    PubMed     Abstract available


    February 2021
  9. YANG X, Zhuang J, Yu H, Cao Q, et al
    Effect of Coronavirus Disease 2019 on Patients with Bladder Cancer in China.
    Urol Int. 2021 Feb 24:1-3. doi: 10.1159/000512895.
    PubMed    


    January 2021
  10. KAYNAR M, Celik ZE, Altintas E, Batur AF, et al
    Comparison of Two Different Bipolar Energy Resources in Transurethral Resection of Bladder Tumors.
    Urol Int. 2021;105.
    PubMed     Abstract available


  11. IZOL V, Deger M, Ozden E, Bolat D, et al
    The Effect of Diagnostic Ureterorenoscopy on Intravesical Recurrence in Patients Undergoing Nephroureterectomy for Primary Upper Tract Urinary Carcinoma.
    Urol Int. 2021;105.
    PubMed     Abstract available


  12. YANG C, Lv Z, Li Y
    Reduction of Bladder Volume after BCG Immunotherapy.
    Urol Int. 2021;105.
    PubMed     Abstract available


    December 2020
  13. RABER M, Buchholz N, Vercesi A, Hendawi NA, et al
    Treatment of Large Non-Muscle-Invasive Bladder Cancer: The Potential Role of Neoadjuvant Intravesical Chemotherapy.
    Urol Int. 2020 Dec 17:1-6. doi: 10.1159/000512052.
    PubMed     Abstract available


    August 2020
  14. MAISCH P, Retz M, Gschwend JE, Koll F, et al
    Clinical Practice Guidelines for Bladder Cancer: A Systematic Review and Meta-Analysis Using the AGREE II Instrument.
    Urol Int. 2020 Aug 21:1-10. doi: 10.1159/000509431.
    PubMed     Abstract available


    July 2020
  15. CHEN G, Yang T, Shao Q, Zhang M, et al
    Sub-Staging-Specific Differences in Recurrence-Free, Progression-Free, and Cancer-Specific Survival for Patients with T1 Bladder Cancer: A Systematic Review and Meta-Analysis.
    Urol Int. 2020 Jul 1:1-7. doi: 10.1159/000506238.
    PubMed     Abstract available


    June 2020
  16. WU J, Wang YC, Luo WJ, Dai B, et al
    Diagnostic Performance of Confocal Laser Endomicroscopy for the Detection of Bladder Cancer: Systematic Review and Meta-Analysis.
    Urol Int. 2020 Jun 18:1-10. doi: 10.1159/000508417.
    PubMed     Abstract available


  17. NAKANE K, Enomoto T, Hishida S, Tomioka M, et al
    The Utility and Efficacy of Laparoscopic Radical Cystectomy in Patients with Muscle-Invasive Bladder Cancer at a Single Institution.
    Urol Int. 2020 Jun 17:1-7. doi: 10.1159/000508192.
    PubMed     Abstract available


  18. BUSETTO GM, Porreca A, Del Giudice F, Maggi M, et al
    SARS-CoV-2 Infection and High-Risk Non-Muscle-Invasive Bladder Cancer: Are There Any Common Features?
    Urol Int. 2020 Jun 9:1-13. doi: 10.1159/000509065.
    PubMed     Abstract available


    May 2020
  19. XU J, Wang C, Ouyang J, Sun J, et al
    Efficacy and Safety of Transurethral Laser Surgery Versus Transurethral Resection for Non-Muscle-Invasive Bladder Cancer: A Meta-Analysis and Systematic Review.
    Urol Int. 2020 May 27:1-14. doi: 10.1159/000506655.
    PubMed     Abstract available


  20. SERRETTA V, Di Maida F, Baiamonte D, Vella M, et al
    Does Smoking Cessation at Primary Diagnosis Reduce the Recurrence Risk of Nonmuscle-Invasive Bladder Cancer? Results of a Prospective Study.
    Urol Int. 2020 May 5:1-6. doi: 10.1159/000507122.
    PubMed     Abstract available


    March 2020
  21. SUAREZ-IBARROLA R, Hein S, Farin E, Waldbillig F, et al
    Current Standards in the Endoscopic Management of Bladder Cancer: A Survey Evaluation among Urologists in German-Speaking Countries.
    Urol Int. 2020 Mar 25:1-7. doi: 10.1159/000506653.
    PubMed     Abstract available


    January 2020
  22. YANG H, Lin J, Gao P, He Z, et al
    Is the En Bloc Transurethral Resection More Effective than Conventional Transurethral Resection for Non-Muscle-Invasive Bladder Cancer? A Systematic Review and Meta-Analysis.
    Urol Int. 2020 Jan 7:1-8. doi: 10.1159/000503734.
    PubMed     Abstract available


  23. SUZUKI K, Hinata N, Inoue TA, Nakamura I, et al
    Comparison of the Perioperative and Postoperative Outcomes of Ileal Conduit and Cutaneous Ureterostomy: A Propensity Score-Matched Analysis.
    Urol Int. 2020;104.
    PubMed     Abstract available


  24. POLETAJEW S, Krajewski W, Adamowicz J, Kolodziej A, et al
    Management of Intradiverticular Bladder Tumours: A Systematic Review.
    Urol Int. 2020;104.
    PubMed     Abstract available


  25. JOKISCH JF, Grimm T, Buchner A, Kretschmer A, et al
    Preoperative Thrombocytosis in Patients Undergoing Radical Cystectomy for Urothelial Cancer of the Bladder: An Independent Prognostic Parameter for an Impaired Oncological Outcome.
    Urol Int. 2020;104.
    PubMed     Abstract available


  26. ZHU C, Deng Z, Yuan L, Su J, et al
    Transurethral-Assisted Transumbilical Laparoendoscopic Single-Site Radical Cystectomy: Initial Short-Term Experience.
    Urol Int. 2020;104.
    PubMed     Abstract available


  27. SARIER M, Sepin N, Keles Y, Imir L, et al
    Is There any Association between Urothelial Carcinoma of the Bladder and Human Papillomavirus? A Case-Control Study.
    Urol Int. 2020;104.
    PubMed     Abstract available


  28. FROEHNER M, Koch R, Heberling U, Borkowetz A, et al
    Validation of a Questionnaire-Suitable Comorbidity Index in Patients Undergoing Radical Cystectomy.
    Urol Int. 2020;104.
    PubMed     Abstract available


  29. FEDELI U, De Paoli A, Corti MC, Cacciamani GE, et al
    Perioperative Mortality and Long-Term Survival after Radical Cystectomy: A Population-Based Study in a Southern European Country on 4,389 Patients.
    Urol Int. 2020;104.
    PubMed     Abstract available


  30. TAMALUNAS A, Buchner A, Kretschmer A, Jokisch F, et al
    Impact of Routine Laboratory Parameters in Patients Undergoing Radical Cystectomy for Urothelial Carcinoma of the Bladder: A Long-Term Follow-Up.
    Urol Int. 2020;104.
    PubMed     Abstract available


    December 2019
  31. ZIEGELMUELLER BK, Jokisch JF, Buchner A, Grimm T, et al
    Long-Term Follow-Up and Oncological Outcome of Patients Undergoing Radical Cystectomy for Bladder Cancer following an Enhanced Recovery after Surgery (ERAS) Protocol: Results of a Large Randomized, Prospective, Single-Center Study.
    Urol Int. 2019 Dec 4:1-7. doi: 10.1159/000504236.
    PubMed     Abstract available


    October 2019
  32. FROEHNER M, Muallah D, Koch R, Hubler M, et al
    Socioeconomic Status-Related Parameters as Predictors of Competing (Non-Bladder Cancer) Mortality after Radical Cystectomy.
    Urol Int. 2019 Oct 22:1-8. doi: 10.1159/000502781.
    PubMed     Abstract available


    September 2019
  33. HAUTMANN RE, Bolenz C, Volkmer B
    Unexpected Early Oncologic Mortality after Open Radical Cystectomy for Bladder Cancer: Who Is to Be Blamed?
    Urol Int. 2019 Sep 27:1-6. doi: 10.1159/000503398.
    PubMed     Abstract available


    August 2019
  34. YOO SH, Kim H, Kwak C, Kim HH, et al
    Late Recurrence of Bladder Cancer following Radical Cystectomy: Characteristics and Outcomes.
    Urol Int. 2019 Aug 28:1-6. doi: 10.1159/000502656.
    PubMed     Abstract available


  35. CARANDO R, Zazzara M, Cotrufo S, Ludovico GM, et al
    Intravesical Treatment with Electro-Mediated Administration of Mytomicin C as Prophylaxis for Intermediate and High-Risk Nonmuscle-Invasive Bladder Cancer: A Retrospective Multicenter Study.
    Urol Int. 2019 Aug 28:1-6. doi: 10.1159/000502663.
    PubMed     Abstract available


    June 2019
  36. BI H, Huang Y, Wang G, Ma L, et al
    Impact of Body Mass Index and Pretreatment Hemoglobin Level on Prognosis Following Radical Cystectomy for Bladder Cancer in Males and Females.
    Urol Int. 2019 Jun 18:1-8. doi: 10.1159/000500561.
    PubMed     Abstract available


    March 2019
  37. CARRION A, Diaz F, Raventos C, Lozano F, et al
    Comparison of Outcomes between Standard and Palliative Management for High Grade Non-Muscle Invasive Bladder Cancer in Patients Older than 85 Years.
    Urol Int. 2019 Mar 7:1-7. doi: 10.1159/000496802.
    PubMed     Abstract available


    January 2019
  38. GROEBEN C, Koch R, Baunacke M, Borkowetz A, et al
    In-Hospital Outcomes after Radical Cystectomy for Bladder Cancer: Comparing National Trends in the United States and Germany from 2006 to 2014.
    Urol Int. 2019 Jan 30:1-9. doi: 10.1159/000496347.
    PubMed     Abstract available


  39. MOSCHINI M, Zamboni S, Mattei A, Baumeister P, et al
    Radical Cystectomy in Pathological T4a and T4b Bladder Cancer Patients: Is There Any Space for Sub Stratification?
    Urol Int. 2019 Jan 29:1-8. doi: 10.1159/000493899.
    PubMed     Abstract available


  40. ZIESCHANG H, Koch R, Wirth MP, Froehner M, et al
    Leiomyosarcoma of the Urinary Bladder in Adult Patients: A Systematic Review of the Literature and Meta-Analysis.
    Urol Int. 2019;102:96-101.
    PubMed     Abstract available


  41. LI A, Zhang P, Zhang M, Yang T, et al
    Transurethral Enucleation of Bladder Leiomyoma: A Series of Six Cases and Review of the Literature.
    Urol Int. 2019;102:102-108.
    PubMed     Abstract available


  42. SHIGEMURA K, Tanaka K, Hamasuna R, Ishikawa K, et al
    Efficacy of Prophylactic Antimicrobial Administration of Tazobactam/Piperacillin for Radical Cystectomy with Urinary Diversion: A Multicenter Study.
    Urol Int. 2019;102:293-298.
    PubMed     Abstract available


  43. URBINA-LIMA AD, Roman-Martin AA, Crespo-Santos A, Martinez-Rodriguez A, et al
    Solitary Fibrous Tumor of the Urinary Bladder Associated with Hypoglycemia: An Unusual Case of Doege-Potter Syndrome.
    Urol Int. 2019;103:120-124.
    PubMed     Abstract available


  44. SCHULZ GB, Grimm T, Buchner A, Kretschmer A, et al
    Benefits and Complications during the Stay at an Early Rehabilitation Facility after Radical Cystectomy and Orthotopic Ileum Neobladder Reconstruction.
    Urol Int. 2019;103:350-356.
    PubMed     Abstract available


  45. AZNAR MARTINEZ L, Lopez Cubillana P, Lopez Abad A, Vidal Crespo N, et al
    Bacillus Calmette-Guerin in Immunosuppressed Patient with High-Grade Nonmuscle Invasive Bladder Carcinoma.
    Urol Int. 2019;103:242-244.
    PubMed     Abstract available


    November 2018
  46. SANGUEDOLCE F, Russo D, Mancini V, Selvaggio O, et al
    Human Epidermal Growth Factor Receptor 2 in Non-Muscle Invasive Bladder Cancer: Issues in Assessment Methods and Its Role as Prognostic/Predictive Marker and Putative Therapeutic Target: A Comprehensive Review.
    Urol Int. 2018 Nov 21:1-13. doi: 10.1159/000494359.
    PubMed     Abstract available


  47. LAUSENMEYER EM, Braun K, Breyer J, Gierth M, et al
    Strong Expression of Cancertestis Antigens CTAG1B and MAGEA3 Is Correlated with Unfavourable Histopathological Features and MAGEA3 Is Associated with Worse Progression-Free Survival in Urothelial Bladder Cancer.
    Urol Int. 2018 Nov 1:1-6. doi: 10.1159/000493577.
    PubMed     Abstract available


    September 2018
  48. BOSSCHIETER J, Nieuwenhuijzen JA, Hentschel A, Vis AN, et al
    Value of a Marker Lesion in Non-Muscle-Invasive Bladder Cancer Patients Treated with Interleukin-2 Instillations: A Randomized Controlled Multicentre Trial.
    Urol Int. 2018 Sep 28:1-8. doi: 10.1159/000493159.
    PubMed     Abstract available


  49. KRAJEWSKI W, Zdrojowy R, Dembowski J, Poletajew S, et al
    The Optimal Timing of Restaging Resection before Introduction of Bacillus Calmette-Guerin Immunotherapy in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer.
    Urol Int. 2018 Sep 28:1-9. doi: 10.1159/000491642.
    PubMed     Abstract available


  50. VETTERLEIN MW, Gild P, Marks P, Roschinski J, et al
    Evaluating Guideline Adherence for T1 Bladder Cancer Treatment and Surveillance: A Retrospective German Multicenter Observation.
    Urol Int. 2018 Sep 20:1-8. doi: 10.1159/000493369.
    PubMed     Abstract available


  51. KRAJEWSKI W, Matuszewski M, Poletajew S, Grzegrzolka J, et al
    Are There Differences in Toxicity and Efficacy between Various Bacillus Calmette-Guerin Strains in Bladder Cancer Patients? Analysis of 844 Patients.
    Urol Int. 2018 Sep 18:1-8. doi: 10.1159/000492722.
    PubMed     Abstract available


    August 2018
  52. MARI A, D'Andrea D, Kimura S, Resch I, et al
    Sarcopenia as a Predictive Factor for Response to Upfront Cisplatin-Based Chemotherapy in Patients with Muscle-Invasive Urothelial Bladder Cancer.
    Urol Int. 2018;101:1-4.
    PubMed     Abstract available


    May 2018
  53. DRAEGER DL, Sievert KD, Hakenberg OW
    Psychosocial Distress in Bladder Cancer Stratified by Gender, Age, Treatment, and Tumour Stage.
    Urol Int. 2018 May 14:1-7. doi: 10.1159/000489502.
    PubMed     Abstract available


    March 2018
  54. CERRUTO MA, D'Elia C, Siracusano S, Saleh O, et al
    Health-Related Quality of Life after Radical Cystectomy for Bladder Cancer in Elderly Patients with Ileal Orthotopic Neobladder or Ileal Conduit: Results from a Multicentre Cross-Sectional Study Using Validated Questionnaires.
    Urol Int. 2018 Mar 7. pii: 000487644. doi: 10.1159/000487644.
    PubMed     Abstract available


  55. DOGAN S, Hennig M, Frank T, Struck JP, et al
    Acceptance of Adjuvant and Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer in Germany: A Survey of Current Practice.
    Urol Int. 2018 Mar 6. pii: 000487405. doi: 10.1159/000487405.
    PubMed     Abstract available


    January 2018
  56. ZUCCHI A, Costantini E
    "Nested Type" Bladder Cancer: Myth or Reality?
    Urol Int. 2018 Jan 17. pii: 000486533. doi: 10.1159/000486533.
    PubMed    


  57. TAN P, Xie N, Yang L, Liu L, et al
    Diagnostic Ureteroscopy Prior to Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma Increased the Risk of Intravesical Recurrence.
    Urol Int. 2018;100:92-99.
    PubMed     Abstract available


  58. PALAZZETTI A, Bosio A, Dalmasso E, Destefanis P, et al
    De Novo Bladder Urothelial Neoplasm in Renal Transplant Recipients: A Retrospective, Multicentered Study.
    Urol Int. 2018;100:185-192.
    PubMed     Abstract available


  59. NIEGISCH G, Nini A, Michalski R, Henn A, et al
    Comparison of 2-Year Oncological Outcome and Early Recurrence Patterns in Patients with Urothelial Bladder Carcinoma Treated with Open or Robot-Assisted Radical Cystectomy with an Extracorporeal Urinary Diversion.
    Urol Int. 2018;101:224-231.
    PubMed     Abstract available


  60. GONZALEZ-PEREZ L, Alvarez-Arguelles H, Ramos Gutierrez VJ, Hernandez SG, et al
    Bladder Fetal Rhabdomyoma Intermediate Type.
    Urol Int. 2018;101:240-244.
    PubMed     Abstract available


  61. SANGUEDOLCE F, Landriscina M, Ambrosi A, Tartaglia N, et al
    Bladder Metastases from Breast Cancer: Managing the Unexpected. A Systematic Review.
    Urol Int. 2018;101:125-131.
    PubMed     Abstract available


  62. FERRO M, Vartolomei MD, Cantiello F, Lucarelli G, et al
    High-Grade T1 on Re-Transurethral Resection after Initial High-Grade T1 Confers Worse Oncological Outcomes: Results of a Multi-Institutional Study.
    Urol Int. 2018;101:7-15.
    PubMed     Abstract available


  63. BEN BAHRIA-SEDIKI I, Chebil M, Sampaio C, Martel-Frachet V, et al
    Prognostic Value of Soluble Death Receptor Ligands in Patients with Transitional Cell Carcinoma of Bladder.
    Urol Int. 2018;100:476-484.
    PubMed     Abstract available


  64. GIERTH M, Zeman F, Denzinger S, Vetterlein MW, et al
    Influence of Body Mass Index on Clinical Outcome Parameters, Complication Rate and Survival after Radical Cystectomy: Evidence from a Prospective European Multicentre Study.
    Urol Int. 2018;101:16-24.
    PubMed     Abstract available


  65. TAE BS, Ku JH, Kwak C, Kim HH, et al
    Comparison of Renal Function after Radical Surgery for Upper Tract Urothelial Carcinoma versus Renal Cell Carcinoma: Propensity Score Matching.
    Urol Int. 2018;101:400-408.
    PubMed     Abstract available


  66. BO S, Donghao S, Guangqi K, Ye T, et al
    CC Chemokine Ligand 18 Promotes Cell Proliferation and Metastasis of Urothelial Carcinoma via Activating PI3K/mTOR Signaling in Patient with Renal Transplantation.
    Urol Int. 2018;101:450-458.
    PubMed     Abstract available


    December 2017
  67. ZATTONI F, Palumbo V, Giannarini G, Crestani A, et al
    Perioperative Outcomes and Early Survival in Octogenarians Who Underwent Radical Cystectomy for Bladder Cancer.
    Urol Int. 2017 Dec 7. pii: 000478990. doi: 10.1159/000478990.
    PubMed     Abstract available


    June 2017
  68. NAGAO K, Hara T, Nishijima J, Shimizu K, et al
    The Efficacy of Trimodal Chemoradiotherapy with Cisplatin as a Bladder-Preserving Strategy for the Treatment of Muscle-Invasive Bladder Cancer.
    Urol Int. 2017 Jun 21. doi: 10.1159/000477912.
    PubMed     Abstract available


  69. POLETAJEW S, Zapala P, Radziszewski P
    Safety and Efficacy of Intravesical Bacillus Calmette-Guerin Immunotherapy in Patients with Non-Muscle-Invasive Bladder Cancer Presenting with Asymptomatic Bacteriuria: A Systematic Review.
    Urol Int. 2017 Jun 10. doi: 10.1159/000477673.
    PubMed     Abstract available


    April 2017
  70. BALCI M, Tuncel A, Keten T, Guzel O, et al
    Comparison of Monopolar and Bipolar Transurethral Resection of Non-Muscle Invasive Bladder Cancer.
    Urol Int. 2017 Apr 6. doi: 10.1159/000467397.
    PubMed     Abstract available


    March 2017
  71. NAKAMURA Y, Yoshida S, Tanaka H, Inoue M, et al
    Potential Utility of Diffusion-Weighted Magnetic Resonance Imaging in Diagnosis of Residual Bladder Cancer before Second Transurethral Resection.
    Urol Int. 2017 Mar 1. doi: 10.1159/000456722.
    PubMed     Abstract available


    February 2017
  72. MOSCHINI M, Shariat SF, Freschi M, Soria F, et al
    Impact of Prostate Involvement on Outcomes in Patients Treated with Radical Cystoprostatectomy for Bladder Cancer.
    Urol Int. 2017 Feb 1. doi: 10.1159/000454736.
    PubMed     Abstract available


    January 2017
  73. LONG X, Qi L, Zu X, Li Y, et al
    Prevention of Recurrent Bladder Tumors after Nephroureterectomy for Primary Upper Urinary Tract Urothelial Carcinoma: An Individualized Selection Strategy Based on Patient Risk Stratification Is Needed.
    Urol Int. 2017;98:312-319.
    PubMed     Abstract available


  74. WOLTERS M, Oelke M, Lutze B, Weingart M, et al
    Deep Surgical Site Infections after Open Radical Cystectomy and Urinary Diversion Significantly Increase Hospitalisation Time and Total Treatment Costs.
    Urol Int. 2017;98:268-273.
    PubMed     Abstract available


    December 2016
  75. BREYER J, Otto W, Wirtz RM, Wullich B, et al
    ERBB2 Expression as Potential Risk-Stratification for Early Cystectomy in Patients with pT1 Bladder Cancer and Concomitant Carcinoma in situ.
    Urol Int. 2016.
    PubMed     Abstract available


  76. D'ELIA C, Comploj E, Cerruto MA, Trenti E, et al
    90-Day Mortality after Radical Cystectomy for Bladder Cancer: Prognostic Factors in a Multicenter Case Series.
    Urol Int. 2016.
    PubMed     Abstract available


    January 2016
  77. SOORIAKUMARAN P, Chiocchia V, Dutton S, Pai A, et al
    Predictive Factors for Time to Progression after Hyperthermic Mitomycin C Treatment for High-Risk Non-Muscle Invasive Urothelial Carcinoma of the Bladder: An Observational Cohort Study of 97 Patients.
    Urol Int. 2016;96:83-90.
    PubMed     Abstract available


  78. SERRETTA V, Scalici Gesolfo C, Alonge V, Cicero G, et al
    Does the Compliance to Intravesical BCG Differ between Common Clinical Practice and International Multicentric Trials?
    Urol Int. 2016;96:20-4.
    PubMed     Abstract available


  79. MARTINI T, Aziz A, Roghmann F, Rink M, et al
    Prediction of Locally Advanced Urothelial Carcinoma of the Bladder Using Clinical Parameters before Radical Cystectomy--A Prospective Multicenter Study.
    Urol Int. 2016;96:57-64.
    PubMed     Abstract available


  80. MILLER K, Morant R, Stenzl A, Zuna I, et al
    A Phase II Study of the Central European Society of Anticancer-Drug Research (CESAR) Group: Results of an Open-Label Study of Gemcitabine plus Cisplatin with or without Concomitant or Sequential Gefitinib in Patients with Advanced or Metastatic Transi
    Urol Int. 2016;96:5-13.
    PubMed     Abstract available


  81. TANAKA H, Yoshida S, Komai Y, Sakai Y, et al
    Clinical Value of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Upper Tract Urothelial Carcinoma: Impact on Detection of Metastases and Patient Management.
    Urol Int. 2016;96:65-72.
    PubMed     Abstract available


  82. GAKIS G, Efstathiou JA, Daneshmand S, Keegan KA, et al
    Oncological Outcomes of Patients with Concomitant Bladder and Urethral Carcinoma.
    Urol Int. 2016;97:134-41.
    PubMed     Abstract available


  83. D''AGOSTINO D, Racioppi M, Pugliese D, Ragonese M, et al
    Postoperative Quality of Life in Patients with Ileal Neobladder at Short-, Intermediate- and Long-Term Follow-Up.
    Urol Int. 2016;97:54-60.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: